ImmunityBio, Inc. (IBRX) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped IBRX stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: ImmunityBio, Inc. showcases outstanding revenue growth, robust development pipelines, and favorable buy-side consensus forecasts. Challenges such as regulatory scrutiny and patent disputes must be monitored closely but do not heavily detract from its long-term bullish outlook. Investors should expect significant price appreciation potential with moderate risk. The saved 1-year distribution is P10 $5.5, P50 $10, and P90 $12.
Last analyzed · Model: gpt-4o
ImmunityBio, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $5.5 | Pessimistic plausible scenario |
| P50 | $10 | Median scenario |
| P90 | $12 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
ImmunityBio, Inc. demonstrates strong potential, given its rapid revenue growth estimate, recent positive trial data, and. analyst consensus with a strong buy rating. However, regulatory challenges and recent market volatility introduce some caution.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this IBRX analysis generated?
April 30, 2026.
Is this a guaranteed IBRX prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full IBRX stock analysis · IBRX sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.